A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox–Gastaut syndrome
Soticlestat did not demonstrate efficacy versus placebo in reducing MMD seizure frequency; the safety findings were consistent with those of previous studies. These data suggest that targeting cholesterol 24-hydroxylase is not a suitable pharmacotherapeutic strategy for LGS.
Authors
- Mahnaz Asgharnejad (ORCID: https://orcid.org/0000-0001-8060-2148)
- P. P. Mitra
- Ružica Kravljanac (ORCID: https://orcid.org/0000-0002-5481-9754)
- Cecil D. Hahn (ORCID: https://orcid.org/0000-0002-0887-8761)
- Anna Altmann
- Philipp von Rosenstiel (ORCID: https://orcid.org/0000-0003-1709-1271)
- Dennis Dlugos (ORCID: https://orcid.org/0000-0003-3088-7645)
- E. Neil G. Marsh (ORCID: https://orcid.org/0000-0003-1713-1683)
- Jimmy Schiemann
- Wei‐Ping Liao (ORCID: https://orcid.org/0000-0001-9929-9185)
- Venkatesha Murthy
- S. Sheikh
- Yasir Khan
- Stéphane Auvin
- Katsumi Imai
- Renzo Guerrini
Institutions
- Children's Hospital of Philadelphia (US)
- Inserm (FR)
- Délégation Paris 7 (FR)
- Institut Universitaire de France (FR)
- Hospital for Sick Children (CA)
- Sorbonne Paris Cité (FR)
- National Epilepsy Center (JP)
- Meyer Children's Hospital (IT)
- Szent János Kórház (HU)
- Hôpital Robert-Debré (FR)
- Institute of Public Health of Serbia (RS)
- Takeda (United States) (US)
- NeuroDiderot (FR)
- University of Florence (IT)
- University of Pennsylvania (US)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Epilepsia
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1002/epi.70216
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00